Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology Annual Meeting and in a Company-sponsored webinar .
CAMBRIDGE, Mass., Sept. 25, 2023 Editas Medicine, Inc. , a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and.
CAMBRIDGE, Mass., Sept. 25, 2023 Editas Medicine, Inc. , a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief.